Nurix Therapeutics Accounts Payable

Nurix Therapeutics (NRIX) currently reports a accounts payable of $12M as of May 2026. That compares with $6M in the prior-year period — up 105.0% year over year. Use the charts on this page to explore Nurix Therapeutics's accounts payable history and peer comparisons.

Nurix Therapeutics's accounts payable increased from $6M to $12M — a 105.0% year-over-year increase (period ending May 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Nurix Therapeutics reported $12M in accounts payable as of May 2026. That compares with $6M in the prior-year period — up 105.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $12M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Nurix Therapeutics, and consider following NRIX for alerts when major investors trade the stock.

Nurix Therapeutics is classified in the Healthcare sector. On accounts payable, it currently shows $12M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NRIX with unrelated industries.